Zai Lab Ltd (ZLAB) SEC filings

ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30471% above fair value

$24.60−1.44 (-5.53%)

Close on Nov 13, 2026Market cap $3.82BP/E –Yield –

SEC filings

40 of Zai Lab's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Oct 22, 2026	Oct 23, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 17, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 21, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 17, 2026	Apr 28, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 26, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Oct 13, 2025	Oct 16, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 18, 2025	Jun 18, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 18, 2025	Apr 29, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 27, 2025	Feb 27, 2025	SEC EDGAR
Current report	8-K	Jan 2, 2025	Jan 3, 2025	SEC EDGAR
Current report	8-K	Nov 14, 2024	Nov 15, 2024	SEC EDGAR
Current report	8-K	Nov 13, 2024	Nov 13, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 12, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Aug 6, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Jul 9, 2024	Jul 9, 2024	SEC EDGAR
Current report	8-K	Jun 18, 2024	Jun 18, 2024	SEC EDGAR
Current report	8-K	Jun 11, 2024	Jun 11, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 18, 2024	Apr 29, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Feb 27, 2024	SEC EDGAR
Current report	8-K	Feb 27, 2024	Feb 27, 2024	SEC EDGAR
Current report	8-K	Feb 5, 2024	Feb 8, 2024	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2022	Dec 22, 2023	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Zai Lab's annual and quarterly filings with the SEC
Per-share figures adjusted for the 10-for-1 split on Mar 30, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ZLAB.

Compare: ZLAB vs HCM · ZLAB vs AAPG · ZLAB vs SNDX · ZLAB vs ZYME · ZLAB vs ARQT

Revenue growth0.0% · median 78.9%

Operating margin-63.0% · median -27.4%

Net margin-44.9% · median -22.9%

Company	Revenue	Growth
ARQT	$508.68M	+60.0%
ZLAB	$441.73M	+0.0%
SNDX	$289.68M	+159.7%
ZYME	$265.97M	+97.8%
HCM	$204.89M	-4.3%
AAPG	–	–

Company

Next earnings (est.): Feb 25, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 1,784
Held by institutions: 10.1%
Auditor: KPMG LLP
SEC CIK: 1704292

Advertisement
300 × 250

See a number that looks wrong?